Gabapentin Tablet
Product Images NDC 68071-2206

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2206). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2206 1)

Label for Gabapentin 800 mg oral tablets by NuCare Pharmaceuticals, Inc. The label indicates a package size of 100 tablets with NDC 68071-2206-1. It includes manufacturer and packaging information, storage instructions, barcode, lot details, expiration date, and a warning to keep out of reach of children.*

FDA Label Image

Figure 1 (Image 01)

A line graph presenting the mean pain score over an 8-week period for two groups: placebo and Gabapentin at 3600 mg/day. The x-axis represents time in weeks, while the y-axis shows the mean pain score. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain scores for the Gabapentin group compared to the placebo group over time.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing the mean pain score over a 7-week period, comparing three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, divided into a 3-week dose titration period followed by a 4-week fixed dose period, while the y-axis shows the mean pain score ranging from 0 to 10.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing pain response outcomes. Study 1 compares placebo (PBO) at 12% versus Gabapentin 3600 mg (GBP 3600) at 29%. Study 2 compares placebo (PBO) at 14% versus Gabapentin 1800 mg (GBP 1800) at 32% and Gabapentin 2400 mg (GBP 2400) at 34%. Statistical significance indicators (** p < 0.01, *** p < 0.001) accompany some bars.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula table showing the calculation for creatinine clearance (CLCr). The formula accounts for age in years, weight in kilograms, serum creatinine in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing its cyclohexane ring bonded to aminomethyl and acetic acid groups, representing the active ingredient in tablet form by NuCare Pharmaceuticals, Inc.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot comparing difference percentages versus daily dose (mg) of Gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose from 600 mg to 1800 mg, while the y-axis shows difference percentage from 0% to 22%. Marker shapes and shading distinguish the studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.